Noetic Fund careers

The Noetic Psychedelic Fund believes the psychedelic pharmaceutical industry is only just emerging and that it will experience exponential growth over the coming decade as new psychedelic-based medicines and therapies are approved by national regulators and adopted by mainstream medicine.

Psychedelic medicine offers:

∙Higher efficacy rates
∙Minimal toxicity
∙Lower treatment costs
∙Customized solutions to those suffering from medical and mental health disorders.

These breakthroughs will help transform the mental healthcare industry to move from treating a patient’s symptoms to providing long-term holistic solutions to patient problems.

This nascent industry will offer first-movers, entrepreneurs and investors alike, a myriad of opportunities. We believe this opportunity set will manifest across intellectual property, medicine research and development, therapeutic modalities and networks, education, diagnostic technologies, integrated and holistic wellness centres and beyond.

Psychedelic-based medicines and their related therapies are generally unknown, under-researched and hard-to-value by the investment industry. This creates rare and fertile ground for first-mover investors. With opportunities abound to invest in and partner with medical and academic researchers, entrepreneurs, nascent pharmaceutical companies and other thought leaders, GHP is building a multi-faceted investment and merchant banking platform to help early-stage companies bring their novel medicines and technologies to market.